CRA was retained in an international arbitration between two Japanese affiliates of multinational pharmaceutical companies. The dispute concerned Respondent’s performance under a co-promotion agreement. CRA’s team of life sciences consultants assessed indicators of commercially reasonable efforts using various industry data sources. The CRA team also quantified Claimant’s loss resulting from the alleged inadequate performance under the agreement, and responded to Respondent’s expert regarding damages alleged by Respondent.
Uranium: A primer for dispute practitioners
In this Insights piece, CRA’s Jim Burrows and Saurabh Singh, assess the trends in uranium supply, demand, and prices and examine the potential impact of...